Secondary outcomes are biomarkers of AD pathology and neurodegeneration (Aβ42, Aβ40, p‐tau217, p‐tau181, BD‐tau, GFAP, NfL) and growth factors (BDNF, IGF‐1), measured through blood samples collected at pre‐ and post‐condition (at 3, 50, 70 min). The gene discussed is GFAP; the disease is Alzheimer disease.